Oppenheimer Maintains Outperform on TransMedics Gr, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group (NASDAQ:TMDX) but lowers the price target from $200 to $125.
October 29, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oppenheimer has maintained its Outperform rating for TransMedics Group but has significantly lowered the price target from $200 to $125, indicating a more cautious outlook.
The maintenance of an Outperform rating suggests continued confidence in the company's performance, but the significant reduction in the price target from $200 to $125 indicates a more cautious outlook, likely due to revised expectations or market conditions. This could lead to a short-term negative impact on the stock price as investors adjust to the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100